Current stock page

Catalysts

TVTX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

TVTXTravere Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$50.65−$0.91 (−1.76%)

Latest quote

  • Momentum
    67
  • Value
    69
  • Quality
    63
  • Risk resilience
    55
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 18, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 64/100

Momentum 67/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 41.44%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 67/100AIQ Edge 7/10 Above Peers
Beat rate
38%
3 of 8 reported periods
Average surprise
-108.5%
Across covered historical reports
Latest result
-891.9%
Nov 2, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 2, 2026—-$0.06-$0.55-891.9%$195.29M$224.56M
Aug 4, 2026—-$0.13-$0.37-174.8%$157.27M$169.58M
May 4, 2026—-$0.30-$0.39-30.0%$136.23M$127.2M
Feb 19, 2026—$0.03$0.03+0.0%$144.55M$129.69M
Oct 30, 2025—-$0.31$0.28+190.3%$146.98M$164.86M
Aug 6, 2025—-$0.28-$0.14+50.0%$99.55M$114.45M
May 1, 2025—-$0.55-$0.47+14.5%$88.8M$81.73M
Feb 20, 2025—-$0.58-$0.73-25.9%$72.38M$74.79M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
14
Buy
1
Hold
12-month analyst target
$89.00
+75.72% versus current price
Based on 15 analyst observations. Targets are estimates, not predictions.
Low target
$89.00
+75.72% vs latest price
Average target
$89.00
+75.72% vs latest price
High target
$89.00
+75.72% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 18, 2027

Next known earnings or reporting date.

EPS estimate$0.44

Current analyst expectation for the upcoming report.

Revenue estimate$247.51M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score67

Where event reaction would show up first.

AIQ score64/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
15
Average target
$89.00
Target upside
75.72%
Target range
$89.00 - $89.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
5
Neutral
0
Negative
0
seekingalpha.com · Nov 3, 2026

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call November 2, 2026 4:30 PM ESTCompany ParticipantsEric Dube - President, CEO & DirectorPeter...

gurufocus.com · Oct 2, 2026

Travere Therapeutics (TVTX) to Present New FILSPARI Data at ASN Kidney Week 2026

On October 02, 2026, Travere Therapeutics Inc (NASDAQ: TVTX) announced it will present nine new studies, including five oral reports, at the American Society of

gurufocus.com · Sep 23, 2026

TVTX Looks 57.0% Overvalued on GF Value™

On September 23, 2026, Travere Therapeutics Inc (NASDAQ: TVTX) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent

gurufocus.com · Sep 22, 2026

TVTX Looks 64.1% Overvalued on GF Value™

On September 21, 2026, Travere Therapeutics Inc (NASDAQ: TVTX) announced a leadership transition with Bradley Campbell named as the incoming CEO effective Decem

rttnews.com · Sep 11, 2026

Show Me The Money: Filspari Powers Travere Therapeutics' Growth

Shares of Travere Therapeutics Inc. (TVTX) touched a 52-week high of $68.59 yesterday, reflecting the meaningful progress made across its key growth areas and the continued momentum in its business.

Open full news and sentiment

TVTX Catalysts FAQ

What are the next catalysts for TVTX stock?

TVTX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TVTX stock?

Upcoming events that could move TVTX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TVTX's next earnings report affect the stock?

TVTX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TVTX stock higher?

TVTX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TVTX stock?

TVTX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.